查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1411730

擴大性心肌病藥物市場：按藥物類別、治療類型、給藥途徑、最終用戶、配銷通路- 全球預測 2024-2030

Dilated Cardiomyopathy Therapeutics Market by Drug class, Treatment Type, Route of Administration, End-User, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

擴大性心肌病藥物市場規模預計2023年為4.215億美元，預計2024年將達4.5676億美元，複合年成長率為7.79%，2030年將達到7.1265億美元。

擴大性心肌病藥物的全球市場

主要市場統計
基準年[2023] 4.215 億美元
預測年份 [2024] 45676萬美元
預測年份 [2030] 71265萬美元
複合年成長率（%） 7.79%
擴張型心肌病變治療藥物市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估擴大性心肌病藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對擴大性心肌病治療市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-擴大性心肌病治療藥物市場的市場規模和預測是多少？

2-擴大性心肌病藥物市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3-擴大性心肌病藥物市場的技術趨勢和法律規範是什麼？

4-擴大性心肌病治療市場主要供應商的市場佔有率是多少？

5-進入擴大性心肌病藥物市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 心血管疾病的盛行率和有效治療的必要性
      • 疾病的早​​期診斷和治療趨勢
      • 提高人們對心血管疾病認知的政府措施和計劃
    • 抑制因素
      • 擴大性心肌病的治療費用很高
    • 機會
      • 精準醫療在擴大性心肌病治療的應用
      • 持續研發治療擴大性心肌病的有效藥物和治療方法
    • 任務
      • 與擴大性心肌病藥物相關的副作用
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章依藥物類別擴大性心肌病藥物市場

  • 醛固酮拮抗
  • 血管收縮素II受體阻斷劑
  • 血管收縮素轉化酵素(ACE) 抑制劑
  • BETA 受體阻斷藥

第7章依治療類型分類的擴大性心肌病藥物市場

  • 心臟去顫器/心臟去顫器
  • 心臟泵
  • 植入式裝置
  • 藥品

第8章擴大性心肌病藥物市場：依給藥途徑

  • 口服
  • 胃腸外的

第9章擴大性心肌病藥物市場：依最終用戶分類

  • 醫院
  • 調查機構
  • 專科診所

第10章擴大性心肌病藥物市場：依配銷通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章北美和南美擴大性心肌病藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區擴大性心肌病藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲擴大性心肌病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：按主要企業分類
  • 主要企業競爭情境分析

第15章競爭產品組合

  • 主要公司簡介
    • AbbVie Inc.
    • Amgen Inc.
    • Amicus Therapeutics
    • Astellas Pharma Inc
    • AstraZeneca plc
    • Bayer AG
    • Biogen Inc.
    • BioMarin Pharmaceutical Inc
    • CH Boehringer Sohn AG & Co. KG
    • Daiichi Sankyo Company, Limited
    • Eli Lilly and Company
    • Gilead Sciences, Inc.
    • GlaxoSmithKline（GSK）
    • Johnson & Johnson Services, Inc.
    • Kyowa Kirin Co, Ltd
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Roche Holding AG
    • Sanofi SA
    • Sarepta Therapeutics
    • Teva Pharmaceutical Industries Ltd.
    • The Bristol-Myers Squibb Company
    • The Takeda Pharmaceutical Company Limited
    • Vertex Pharmaceuticals
    • Viatris Inc.
  • 主要產品系列

第16章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-8E22B61932E2

[192 Pages Report] The Dilated Cardiomyopathy Therapeutics Market size was estimated at USD 421.50 million in 2023 and expected to reach USD 456.76 million in 2024, at a CAGR 7.79% to reach USD 712.65 million by 2030.

Global Dilated Cardiomyopathy Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 421.50 million
Estimated Year [2024] USD 456.76 million
Forecast Year [2030] USD 712.65 million
CAGR (%) 7.79%
Dilated Cardiomyopathy Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Dilated Cardiomyopathy Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Dilated Cardiomyopathy Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Dilated Cardiomyopathy Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amicus Therapeutics, Astellas Pharma Inc, AstraZeneca plc, Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc, C.H. Boehringer Sohn AG & Co. KG, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline (GSK), Johnson & Johnson Services, Inc., Kyowa Kirin Co, Ltd, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sarepta Therapeutics, Teva Pharmaceutical Industries Ltd., The Bristol-Myers Squibb Company, The Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Dilated Cardiomyopathy Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug class
    • Aldosterone antagonists
    • Angiotensin II Receptor Blockers
    • Angiotensin-converting enzyme (ACE) Inhibitors
    • Beta-blockers
  • Treatment Type
    • Cardioverter-Defibrillators
    • Heart Pumps
    • Implantable Devices
    • Medication
  • Route of Administration
    • Oral
    • Parenteral
  • End-User
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Dilated Cardiomyopathy Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Dilated Cardiomyopathy Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Dilated Cardiomyopathy Therapeutics Market?

4. What is the market share of the leading vendors in the Dilated Cardiomyopathy Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Dilated Cardiomyopathy Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Dilated Cardiomyopathy Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cardiovascular diseases and the need for effective treatments
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Government initiatives and programs to raise awareness regarding cardiovascular diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of dilated-cardiomyopathy therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Applications of precision medicine in the management of dilated cardiomyopathy
      • 5.1.3.2. Ongoing R&D for the development of efficient drugs and therapies for dilated-cardiomyopathy
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the dilated-cardiomyopathy medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Dilated Cardiomyopathy Therapeutics Market, by Drug class

  • 6.1. Introduction
  • 6.2. Aldosterone antagonists
  • 6.3. Angiotensin II Receptor Blockers
  • 6.4. Angiotensin-converting enzyme (ACE) Inhibitors
  • 6.5. Beta-blockers

7. Dilated Cardiomyopathy Therapeutics Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Cardioverter-Defibrillators
  • 7.3. Heart Pumps
  • 7.4. Implantable Devices
  • 7.5. Medication

8. Dilated Cardiomyopathy Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Dilated Cardiomyopathy Therapeutics Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research Institutes
  • 9.4. Specialty Clinics

10. Dilated Cardiomyopathy Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Americas Dilated Cardiomyopathy Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Dilated Cardiomyopathy Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Dilated Cardiomyopathy Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

  • 15.1. Key Company Profiles
    • 15.1.1. AbbVie Inc.
    • 15.1.2. Amgen Inc.
    • 15.1.3. Amicus Therapeutics
    • 15.1.4. Astellas Pharma Inc
    • 15.1.5. AstraZeneca plc
    • 15.1.6. Bayer AG
    • 15.1.7. Biogen Inc.
    • 15.1.8. BioMarin Pharmaceutical Inc
    • 15.1.9. C.H. Boehringer Sohn AG & Co. KG
    • 15.1.10. Daiichi Sankyo Company, Limited
    • 15.1.11. Eli Lilly and Company
    • 15.1.12. Gilead Sciences, Inc.
    • 15.1.13. GlaxoSmithKline (GSK)
    • 15.1.14. Johnson & Johnson Services, Inc.
    • 15.1.15. Kyowa Kirin Co, Ltd
    • 15.1.16. Merck & Co., Inc.
    • 15.1.17. Novartis AG
    • 15.1.18. Pfizer Inc.
    • 15.1.19. Regeneron Pharmaceuticals, Inc.
    • 15.1.20. Roche Holding AG
    • 15.1.21. Sanofi S.A.
    • 15.1.22. Sarepta Therapeutics
    • 15.1.23. Teva Pharmaceutical Industries Ltd.
    • 15.1.24. The Bristol-Myers Squibb Company
    • 15.1.25. The Takeda Pharmaceutical Company Limited
    • 15.1.26. Vertex Pharmaceuticals
    • 15.1.27. Viatris Inc.
  • 15.2. Key Product Portfolio

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 10. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 16. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 26. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 6. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HEART PUMPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 16. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 236. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET LICENSE & PRICING